MEDIPOST CDMO service

MEDIPOST follows a strong quality policy that adheres to the latest GMP regulations and provide the best CDMO service to our clients based on our extensive experience in product approval obtainment and due diligence.

Global Leader
in Stem Cell Therapeutics

0+
Number of registered patents
in Korea and overseas
0+
Number of national R&D
grants received in Korea
0
Number of private cord blood
units stored
0%
Percentage of
R&D staff

1st Generation Cord Blood-derived Stem Cell Products

CARTISTEM®

Treatment of knee cartilage defects including for patients with Knee Osteoarthritis

CARTISTEM® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma.

PNEUMOSTEM®

Preventive treatment of bronchopulmonary dysplasia(BPD)

PNEUMOSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM®.

2nd Generation Cord Blood-derived Stem Cell Products

SMUP-IA-01

Intra-articular Injectable treatment for osteoarthritis

SMUP-IA-01, SMUP allogeneic umbilical cord blood-derived mesenchymal stem cells, is currently under development for the treatment and prevention of Osteoarthritis. Currently, SMUP-IA-01 is undergoing Phase 2 clinical trial in Korea with IND from the MFDS.

SMUP-IV-01

Intra-venous infusion treatment for diabetic nephropathy

SMUP-IV-01, an SMUP allogeneic umbilical cord blood-derived mesenchymal stem cels, is under development for the treatment and prevention of Diabetic Nephropathy. Currently, SMUP-IV-01 is in the process of applying for phase 1 clinical trial of the MFDS.

Global Leader in Stem Cell Therapeutics

As a global leader in biotechnology with cutting-edge Technologies in Stem Cell Therapeutics, MEDIPOST continues to innovate and challenge to tackle unmet medical needs.